Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices

Michael Antonopoulos,Michael J. Bonios,Stavros Dimopoulos,Evangelos Leontiadis,Aggeliki Gouziouta,Nektarios Kogerakis,Antigone Koliopoulou,Dimitris Elaiopoulos,Ioannis Vlahodimitris,Maria Chronaki,Themistocles Chamogeorgakis,Stavros G. Drakos,Stamatis Adamopoulos

DOI: https://doi.org/10.3390/jcdd11020061

2024-02-16

Journal of Cardiovascular Development and Disease

Abstract:Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer from severe symptoms and frequent hospitalizations and have a dismal prognosis, with a significant socioeconomic burden in health care systems. Patients in this group may be eligible for advanced heart failure therapies, including heart transplantation and chronic mechanical circulatory support with left ventricular assist devices (LVADs). Heart transplantation remains the treatment of choice for eligible candidates, but the number of transplants worldwide has reached a plateau and is limited by the shortage of donor organs and prolonged wait times. Therefore, LVADs have emerged as an effective and durable form of therapy, and they are currently being used as a bridge to heart transplant, destination lifetime therapy, and cardiac recovery in selected patients. Although this field is evolving rapidly, LVADs are not free of complications, making appropriate patient selection and management by experienced centers imperative for successful therapy. Here, we review current LVAD technology, indications for durable MCS therapy, and strategies for timely referral to advanced heart failure centers before irreversible end-organ abnormalities.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to select and apply left ventricular assist devices (LVADs) in the field of heart failure treatment, especially for patients with advanced heart failure (ADHF). With the increase in the incidence of heart failure, especially in the elderly population, and the improvement in survival rates after acute myocardial infarction, more and more patients progress to the ADHF stage. These patients experience problems such as low quality of life, frequent hospitalizations, and high mortality, which impose a huge economic and social burden on the medical system.

Although heart transplantation is still the preferred treatment method for eligible patients, due to factors such as donor organ shortages, long waiting times, and patient comorbidities, heart transplantation is only applicable to a small number of ADHF patients. Therefore, LVADs, as an effective form of long - term mechanical circulatory support (MCS), have become an important alternative treatment option. LVADs can be used as a bridge - to - transplantation (BTT), destination therapy (DT), or a bridge to recovery (BTR).

However, the application of LVADs is not without challenges. Patient selection, progress in LVAD technology, postoperative management, and complication handling are all key factors affecting treatment outcomes. By reviewing current LVAD technologies, indications, and patient selection strategies, the paper aims to provide guidance for clinicians to improve the treatment outcomes and quality of life of ADHF patients. In addition, the paper also discusses the application of LVADs in different clinical scenarios, including their different roles as BTT, DT, BTD (Bridge to Decision), and BTR, and how to optimize treatment decisions based on patients' clinical conditions and INTERMACS classification.